GSK has completed its £2 billion share buyback program to reduce outstanding shares and enhance shareholder returns.
The company is also pursuing a cash tender offer to acquire Nuvalent, Inc. This acquisition strategy aims to strengthen GSK's oncology portfolio.
In the US, the Centers for Medicare & Medicaid Services assigned a permanent J-code to GSK’s multiple myeloma treatment, Blenrep. This billing code becomes effective on July 1, 2026.
The new code will streamline reimbursement for healthcare providers. This change is expected to improve patient access, particularly within community oncology settings.